AstraZeneca scours supply chain for more vaccine doses for Thailand, SE Asia



BANGKOK, July 24 (Reuters) - AstraZeneca Plc AZN.L is "scouring" its global supply chain to try and boost COVID-19 vaccine supplies to Thailand and Southeast Asia, its representative for the country said on Saturday, amidst speculations of local production shortfalls.

The comments come after leaked letters Link showed last week that the drugmaker had offered to supply 5-6 million vaccine doses a month to Thailand, contradicting assertions by Thai officials that the government is owed 10 million a month and 61 million doses by end-2021.

AstraZeneca is "scouring the 20+ supply chains in our worldwide manufacturing network to find additional vaccines for Southeast Asia, including Thailand", James Teague, managing director of AstraZeneca Thailand, said in a statement.

"We are hopeful of importing additional doses in the months ahead," he added.

The drugmaker had previously said vaccine doses for Thailand and Southeast Asia would come from a plant of its Thai partner Siam Bioscience, owned by Thailand's king and a first-time vaccine maker.

Pressure has been mounting on the company after Thailand said it was considering imposing limits Link on exports of locally manufactured AstraZeneca COVID-19 vaccines to shore up domestic supplies, a move that could hit its neighbours, some of which are battling similar or more severe COVID-19 crises.

Siam Bioscience has not commented on reports of production shortfalls or delivery timelines.

Teague said AstraZeneca has delivered 9 million does so far to Thailand and will deliver 2.3 million more next week.

Thailand has fully inoculated just 5.56% of its population of more than 66 million so far, while 18.62% have received at least one dose, government data shows.
Reporting by Patpicha Tanakasempipat; Editing by Kay Johnson and Himani Sarkar

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.